

New approach for the capture of tumorderived exosomes from a prostate cancer cell line

February 21 2017

Specific capture of PSMA+ exosomes from prostate cancer cells




Figure a shows captured exosomes on ligand-baited nanosprings, the exosomes



are indicated by the arrows. Figure b shows a TEM image of captured exosomes following negative staining with phosphotungstic acid (PTA) PH = 7.1. Credit: Springer Science+Business Media New York 2017

In a new paper in Springer's *Journal of Materials Science*, researchers at Washington State University report a new approach for the effective capture of tumor-derived exosomes from a prostate cancer cell line. Exosomes are small secreted vesicles that play a key role in intercellular communication and cancer progression.

Developing effective and high-throughput selective capture technology for exosomes bearing the prostate-specific membrane antigen (PSMA) biomarker is critical for early diagnostic and prognostic evaluation of prostate cancer and treatment planning. It is known that the prostate tumor enzyme-biomarker PSMA is highly enriched in exosomes secreted by PSMA+ prostate cancer cells. A novel biofunctionalized silica nanostructure was designed to selectivity capture tumor-derived exosomes through the interaction of a known PSMA ligand with the PSMA on the exosomes.

This work enables a non-invasive approach for diagnosis and prognosis of prostate cancer. It overcomes many of the limitations of alternative approaches that are often ineffective in isolating tumor-derived exosomes from those derived from normal tissue because of the low recovery yields and the time required for the process.

The concept was demonstrated using a single cancer type (i.e., prostate cancer), but based on the data presented in this study, the authors expect that a broad panel of biomarker ligands can be baited on the silica nanostructures to selectively capture biomarker-positive exosomes from an array of cell types. Further advantages of the approach used in this



study are the ability to isolate a specific subpopulation of exosomes relying on the expression of a specific surface marker as well as improved exosome recovery rate. In the future, the authors envision a microfluidic flow device that will allow for increased exosome capture efficiency and clinical applications.

More information: Parissa Ziaei et al, Silica nanostructured platform for affinity capture of tumor-derived exosomes, *Journal of Materials Science* (2017). DOI: 10.1007/s10853-017-0905-0

Provided by Springer

Citation: New approach for the capture of tumor-derived exosomes from a prostate cancer cell line (2017, February 21) retrieved 10 April 2024 from https://phys.org/news/2017-02-approach-capture-tumor-derived-exosomes-prostate.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.